A perspective on the introduction of universal childhood hepatitis A vaccination in Latin America and the Caribbean

Parellada, C.; Massoc, M.A.; Carrega, María Eugenia Pérez; Guarneros, D.; Petrozzi, Maria Veronica; Cashat-Cruz, Miguel; Homero, M.

doi:10.1016/j.ijid.2018.04.4233

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the 2012 WHO position paper on hepatitis A vaccines stated that national immunization programs may consider inclusion of single-dose inactivated hepatitis A vaccines in childhood immunization schedules [10] based on experience in Argentina [30]. This recommendation was followed by other low and middle income countries of Latin America as Brazil, Chile and Colombia introduced hepatitis A vaccination in their childhood immunization schedules [31]. Other countries outside Latin America have shown similar positive effects after the use of a single-dose hepatitis A vaccine, such as Russia [32].…”

Section: Discussionmentioning

confidence: 99%

The Impact of an Inactivated Hepatitis A Vaccine with One Dose in Brazil: A Retrospective Time-Series

et al. 2021

View full text Add to dashboard Cite

Background: In 2014, a recommended one-dose of inactivated hepatitis A vaccine was included in the Brazilian National Immunization Program targeting children 12–24 months. This decision addressed the low to intermediate endemicity status of hepatitis A across Brazil and the high rate of infection in children and adolescents between 5 and 19 years old. The aim of the study was to conduct a time-series analysis on hepatitis A incidence across age groups and to assess the hepatitis A distribution throughout Brazilian geographic regions. Methods: An interrupted time-series analysis was performed to assess hepatitis A incidence rates before (2010–2013) and after (2015–2018) hepatitis A vaccine program implementation. The time-series analysis was stratified by age groups while a secondary analysis examined geographic distribution of hepatitis A cases. Results: Overall incidence of hepatitis A decreased from 3.19/100.000 in the pre-vaccine period to 0.87/100.000 (p = 0.022) post-vaccine introduction. Incidence rate reduction was higher among children aged 1-4 years old, with an annual reduction of 67.6% in the post-vaccination period against a 7.7% annual reduction in the pre-vaccination period (p < 0.001). Between 2015 and 2018, the vaccination program prevented 14,468 hepatitis A cases. Conclusion: Our study highlighted the positive impact of a recommended one-dose inactivated hepatitis A vaccine for 1–4-years-old in controlling hepatitis A at national level.

show abstract

Section: Discussionmentioning

confidence: 99%

The Impact of an Inactivated Hepatitis A Vaccine with One Dose in Brazil: A Retrospective Time-Series

et al. 2021

View full text Add to dashboard Cite

show abstract

“…En febrero de 2018, Perú se unió a otros países latinoamericanos en incluir la vacuna contra la varicela en su programa de inmunización nacional (9,30). En Uruguay, un estudio hecho después de 6 años de la introducción de la vacuna contra varicela en su calendario nacional a los 12 meses de edad con altas tasas sostenidas de cobertura vacunal, demostró reducción de 81% y 87% de las hospitalizaciones y de las consultas de pacientes ambulatorios relacionadas a varicela, respectivamente (31).…”

Section: Castillo Me Y Colunclassified

Economic Burden of Varicella in Children in Peru from 2011 to 2016

et al. 2019

View full text Add to dashboard Cite

Objetivo: Describir las complicaciones mas frecuentes y la carga económica asociada con la varicela en el Perú. Material y métodos: Estudio multicéntrico de revisión de historias clínicas de pacientes de 1 a 14 años con diagnóstico de varicela entre 2011 y 2016. El uso de recursos de atención médica (URAM) asociados con la varicela, los costos unitarios y la pérdida de trabajo se utilizaron para estimar los costos directos e indirectos, presentados en USD ($). Los datos de costos y URAM se combinaron con estimaciones de carga de enfermedad para calcular el costo total anual de la varicela en el Perú. Resultados: Se incluyeron un total de 179 niños con varicela (101 ambulatorios, 78 hospitalizados). Entre los pacientes ambulatorios, el 5,9 % presentó una o más complicaciones, en comparación con 96,2 % de pacientes hospitalizados. El URAM incluyó el uso de medicamentos de venta libre (72,3 % frente a 89,7 % de pacientes ambulatorios y hospitalizados, respectivamente), medicamentos con receta (30,7 % frente a 94,9 %) y análisis y procedimientos (0,0 % frente a 80,8 %). Los costos directos e indirectos por caso ambulatorio fueron $36 y $62 respectivamente y por caso hospitalizado fueron $548 y $222. El costo anual total asociado con la varicela se estimó en $13 907 146. Conclusión: La varicela está asociada con complicaciones clínicas importantes y elevado URAM en Perú, lo que respalda la necesidad de implementación de un plan de vacunación universal.

show abstract

A perspective on the introduction of universal childhood hepatitis A vaccination in Latin America and the Caribbean

Cited by 2 publications

References 0 publications

The Impact of an Inactivated Hepatitis A Vaccine with One Dose in Brazil: A Retrospective Time-Series

The Impact of an Inactivated Hepatitis A Vaccine with One Dose in Brazil: A Retrospective Time-Series

Economic Burden of Varicella in Children in Peru from 2011 to 2016

Contact Info

Product

Resources

About